TNF inhibitors offered greater protection against fractures than NSAIDs in patients with axial spondyloarthritis (axSpA).

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

AxSpA can bring on plantar fasciitis, which is when inflammation in the heel causes the sole of your foot to hurt. You may ...

Alcohol consumption was associated with lower levels of axSpA disease activity and spinal pain, but may be linked to ...

Study finds TNF inhibitors lower hip and spine fracture risk in axial spondyloarthritis, addressing inflammation-related ...

High-dose nonsteroidal anti-inflammatory drug use among patients with axial spondyloarthritis (axSpA) may not increase the risk of developing hypertension, according to study results presented at the ...

The following is a summary of “Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures,” published in the December 2024 issue of Rheumatology by Driscoll et al.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

UCB SA (OTCMKTS:UCBJY – Get Free Report) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 200 shares, a drop of 80.

MRT-6160 is under development for the treatment of axial spondyloarthritis, rheumatoid arthritis, multiple sclerosis, Myasthenia Gravis, psoriasis, cutaneous lupus erythematosus a ...

Companies like Janssen, Pfizer, UCB, Amgen, and AbbVie are advancing axial spondyloarthritis treatments, focusing on improving symptoms and patient outcomes. LAS ...